Janelle Schrag, MPH; Fitzgerald Draper, MS; Monique Dawkins, EdD, MPA; Lorna Lucas, MSM; Leigh M. Boehmer, PharmD, BCOP
Association of Community Cancer Centers, Rockville, Maryland, USA
The landscape for clinician education in immuno-oncology (IO) has changed dramatically since the first approval of an immune checkpoint inhibitor in 2011. Educational initiatives have had to evolve with the multitude of new IO approvals and indications, as well as continuous integration of these therapies in patient care. As such, an IO census survey was administered and analyzed to better assess the current knowledge and educational needs of the oncology care delivery team.